- Home
- NRIX vs ULH Comparison
NRIX vs ULH Comparison
Compare NRIX & ULH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NRIX
- ULH
- Stock Information
- Founded
- NRIX 2009
- ULH 1932
- Country
- NRIX United States
- ULH United States
- Employees
- NRIX N/A
- ULH N/A
- Industry
- NRIX Biotechnology: Pharmaceutical Preparations
- ULH Trucking Freight/Courier Services
- Sector
- NRIX Health Care
- ULH Industrials
- Exchange
- NRIX Nasdaq
- ULH Nasdaq
- Market Cap
- NRIX 728.6M
- ULH 618.7M
- IPO Year
- NRIX 2020
- ULH 2005
- Fundamental
- Price
- NRIX $10.69
- ULH $21.47
- Analyst Decision
- NRIX Strong Buy
- ULH Hold
- Analyst Count
- NRIX 14
- ULH 1
- Target Price
- NRIX $29.07
- ULH $29.00
- AVG Volume (30 Days)
- NRIX 1.2M
- ULH 43.0K
- Earning Date
- NRIX 10-09-2025
- ULH 10-23-2025
- Dividend Yield
- NRIX N/A
- ULH 1.93%
- EPS Growth
- NRIX N/A
- ULH N/A
- EPS
- NRIX N/A
- ULH 2.31
- Revenue
- NRIX $88,381,000.00
- ULH $1,668,148,000.00
- Revenue This Year
- NRIX $74.59
- ULH N/A
- Revenue Next Year
- NRIX N/A
- ULH $5.57
- P/E Ratio
- NRIX N/A
- ULH $9.44
- Revenue Growth
- NRIX 41.86
- ULH N/A
- 52 Week Low
- NRIX $8.18
- ULH $20.17
- 52 Week High
- NRIX $29.56
- ULH $53.29
- Technical
- Relative Strength Index (RSI)
- NRIX 63.25
- ULH 37.60
- Support Level
- NRIX $8.20
- ULH $20.34
- Resistance Level
- NRIX $10.23
- ULH $22.15
- Average True Range (ATR)
- NRIX 0.50
- ULH 1.02
- MACD
- NRIX 0.27
- ULH -0.23
- Stochastic Oscillator
- NRIX 99.80
- ULH 25.99
About NRIX Nurix Therapeutics Inc. Common stock
Nurix Therapeutics Inc is a biopharmaceutical company focused on the discovery, development and commercialization of oral, small molecule therapies designed to modulate cellular protein levels as a novel treatment approach for cancer and immune disorders. The company's pipeline comprises targeted protein degraders of Brutons tyrosine kinase, or BTK, a B-cell signaling protein, and inhibitors of Casitas B-lineage lymphoma proto-oncogene-B, or CBL-B, an E3 ligase that regulates T cell activation. Its drug candidate from protein degradation portfolio, NX-2127, is an orally available BTK degrader for the treatment of relapsed or refractory B-cell malignancies.
About ULH Universal Logistics Holdings Inc.
Universal Logistics Holdings Inc is an asset-light provider of customized transportation and logistics solutions throughout the United States, and in Mexico, Canada and Colombia. It offers services such as truckload, brokerage, intermodal, dedicated, and value-added services. The company reports into four segments namely trucking, intermodal, company-managed brokerage, and contract logistics. The majority of the revenue is earned from the contract logistics segment.